A late-breaking abstract was released today on a study in which patients were given a higher dose (2.4 mg) of semaglutide than is currently approved for weight management. Semaglutide, a GLP-1 analog drug approved at a higher dose (2mg) in March for type 2 diabetes, only received approval to treat obesity last year. In the STEP 1 trial, 1,961...